Press Releases

With a high reputation for sequencing, microarray analysis, library construction and genotyping, CD Genomics provides reliable services to pharmaceutical and biotechnology companies as well as academia and government agencies. These days, the product manager of CD Genomics announced that the company has recently optimized NGS oncology panels, which can meet the most challenging research processes.

Cancer is a genetic disease, which is induced by the accumulation of harmful DNA mutations in cells. At present, it has been elucidated that the mechanisms of inducing abnormal cell proliferation, differentiation and cancer production are mainly categorized as follows: activating dominant transforming proto-oncogenes by translocations and mutations, inactivating tumor suppressor gene by mutations, and disordering the DNA repair genes.

There are two basic types of gene mutations, namely germline mutations and somatic mutations, depending on where the mutation occurs in the tissue. Germline mutations are genetic changes that can be inherited from our parents that cause cancer. If germline mutations occur in sperm cells or egg cells, it may be passed on from generation to generation. Cancers caused by germline mutations are called hereditary cancers, accounting for 5% to 20% of all cancers.

Somatic mutations are the most common cause of cancer. They occur due to the alterations of genes in specific cells, and then continue to divide many times and form tumors. These mutations are not found in every cell of the human body, and they are not passed from parents to children.

“CD Genomics’ ready-to-use NGS cancer panels utilize targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations, and even to detect low-frequency variations in cancer-associated genes. Targeted NGS sequencing facilitates the sequencing of a large number of genes and samples in a single and cost-effective assay. ” commented vice president of CD Genomics.

CD Genomics offers six related products for research use:

ž   CDAMP® Pan-Cancer 500 Panel Kit

ž   CDAMP® Hereditary Cancer 37 Panel Kit

ž   CDAMP® Cancer Hotspot 65 Panel Kit

ž   CDAMP® Lung Cancer 23 Panel Kit

ž   CDAMP® Breast Cancer Panel Kit

ž   CDAMP® ctDNA 50 Panel Kit

“As a company that specializes in providing genome services and products, CD Genomics has been committed to offering different kinds of ready-to-use NGS cancer panels for cancer-related researches. Targeted NGS sequencing facilitates the sequencing of a large number of genes and samples in a single and cost-effective assay,” said Dr. Charlie.

About CD Genomics

Based on extensive experience in sequencing, microarray analysis, library construction and genotyping, CD Genomics is further developed with the mission to accelerate the entire genetic industry toward breakthrough discoveries.

Contact

Address: 45-1 Ramsey Road, Shirley, NY 11967, USA